Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system

Molecular Therapy

Volumn 19, Issue 8, 2011, Pages 1440-1448

  Zhang, Hongwei ^a,b   Yang, Bin ^a   Mu, Xin ^a,c   Ahmed, Seemin Seher ^a   Su, Qin ^a   He, Ran ^a   Wang, Hongyan ^a   Mueller, Christian ^a   Sena Esteves, Miguel ^a   Brown, Robert ^a   Xu, Zuoshang ^a   Gao, Guangping ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b SOUTH DAKOTA STATE UNIVERSITY   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR 1; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR 2; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR 5; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR 6; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR 6.2; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR 7; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR 9; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR RH.10; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR RH.39; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR RH.43; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN NERVE CELL; BRAIN REGION; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CERVICAL SPINE; CHOROID PLEXUS; CORPUS STRIATUM; DRUG PENETRATION; FLUORESCENCE ANALYSIS; GENE TRANSFER; GENETIC TRANSDUCTION; GLIOSIS; HIPPOCAMPUS; HYPOTHALAMUS; LUMBAR SPINE; MEDULLA OBLONGATA; MICROGLIOSIS; MOTONEURON; MOUSE; NEUROLOGIC DISEASE; NEUROSCIENCE; NEWBORN; NONHUMAN; OLFACTORY BULB; PROTEIN EXPRESSION; PURKINJE CELL; THALAMUS; THORACIC SPINE; VIRAL GENE DELIVERY SYSTEM;

ADENO-ASSOCIATED VIRUS 9; MUS;

EID: 79961032418     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.98     Document Type: Article

References (38)

1. Urbaniak Hunter, K, Yarbrough, C and Ciacci, J (2010). Gene- and cell-based approaches for neurodegenerative disease. Adv Exp Med Biol 671: 117-130.
2. Manfredsson, FP and Mandel, RJ (2010). Development of gene therapy for neurological disorders. Discov Med 9: 204-211.
3. Cearley, CN, Vandenberghe, LH, Parente, MK, Carnish, ER, Wilson, JM and Wolfe, JH (2008). Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol Ther 16: 1710-1718.
4. Li, W, Asokan, A, Wu, Z, Van Dyke, T, DiPrimio, N, Johnson, JS et al. (2008). Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 16: 1252-1260. (Pubitemid 351866056)
5. Kells, AP, Hadaczek, P, Yin, D, Bringas, J, Varenika, V, Forsayeth, J et al. (2009). Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci USA 106: 2407-2411.
6. Foust, KD, Wang, X, McGovern, VL, Braun, L, Bevan, AK, Haidet, AM et al. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28: 271-274.
7. Foust, KD, Nurre, E, Montgomery, CL, Hernandez, A, Chan, CM and Kaspar, BK (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27: 59-65.
8. Pardridge, WM (2002). Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1: 131-139. (Pubitemid 41646520)
9. Abbott, NJ, Rönnbäck, L and Hansson, E (2006). Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7: 41-53. (Pubitemid 41828930)
10. Hester, ME, Foust, KD, Kaspar, RW and Kaspar, BK (2009). AAV as a gene transfer vector for the treatment of neurological disorders: novel treatment thoughts for ALS. Curr Gene Ther 9: 428-433.
11. Pardridge, WM (2010). Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. Cold Spring Harb Protoc 2010: pdb.prot5407.
12. Gray, SJ, Blake, BL, Criswell, HE, Nicolson, SC, Samulski, RJ, McCown, TJ et al. (2010). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther 18: 570-578.
13. Duque, S, Joussemet, B, Riviere, C, Marais, T, Dubreil, L, Douar, AM et al. (2009). Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17: 1187-1196.
14. Davidson, BL, Stein, CS, Heth, JA, Martins, I, Kotin, RM, Derksen, TA et al. (2000). Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 97: 3428-3432. (Pubitemid 30183319)
15. Burger, C, Nash, K and Mandel, RJ (2005). Recombinant adeno-associated viral vectors in the nervous system. Hum Gene Ther 16: 781-791. (Pubitemid 40982327)
16. Xiao, X, Li, J, McCown, TJ and Samulski, RJ (1997). Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol 144: 113-124. (Pubitemid 27149611)
17. Kaplitt, MG, Feigin, A, Tang, C, Fitzsimons, HL, Mattis, P, Lawlor, PA et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097-2105. (Pubitemid 46935946)
18. Feigin, A, Kaplitt, MG, Tang, C, Lin, T, Mattis, P, Dhawan, V et al. (2007). Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 104: 19559-19564.
19. Muramatsu, S, Fujimoto, K, Kato, S, Mizukami, H, Asari, S, Ikeguchi, K et al. (2010). A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 18: 1731-1735.
20. McCarty, DM (2008). Self-complementary AAV vectors; advances and applications. Mol Ther 16: 1648-1656.
21. Gao, GP, Alvira, MR, Wang, L, Calcedo, R, Johnston, J and Wilson, JM (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859. (Pubitemid 34994488)
22. Gao, G, Vandenberghe, LH, Alvira, MR, Lu, Y, Calcedo, R, Zhou, X et al. (2004). Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 78: 6381-6388. (Pubitemid 38715936)
23. Lin, G, Finger, E and Gutierrez-Ramos, JC (1995). Expression of CD34 in endothelial cells, hematopoietic progenitors and nervous cells in fetal and adult mouse tissues. Eur J Immunol 25: 1508-1516.
24. Suzuki, K, Kastuno, M, Banno, H and Sobue, G (2009). Pathogenesis- targeting therapeutics for spinal and bulbar muscular atrophy (SBMA). Neuropathology 29: 509-516.
25. Hobert, JA and Dawson, G (2006). Neuronal ceroid lipofuscinoses therapeutic strategies: past, present and future. Biochim Biophys Acta 1762: 945-953. (Pubitemid 44740122)
26. Hebert, MD and Whittom, AA (2007). Gene-based approaches toward Friedreich ataxia therapeutics. Cell Mol Life Sci 64: 3034-3043. (Pubitemid 351152238)
27. Kumar, S, Mattan, NS and de Vellis, J (2006). Canavan disease: a white matter disorder. Ment Retard Dev Disabil Res Rev 12: 157-165.
28. Yamanaka, K, Chun, SJ, Boillee, S, Fujimori-Tonou, N, Yamashita, H, Gutmann, DH et al. (2008). Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11: 251-253. (Pubitemid 351311795)
29. Flossmann, E (2006). Genetics of ischaemic stroke; single gene disorders. Int J Stroke 1: 131-139. (Pubitemid 44151505)
30. Federici, T and Boulis, N (2007). Gene therapy for peripheral nervous system diseases. Curr Gene Ther 7: 239-248. (Pubitemid 47232956)
31. Beutler, AS (2010). AAV provides an alternative for gene therapy of the peripheral sensory nervous system. Mol Ther 18: 670-673.
32. Siegel, RM and Callaway, EM (2004). Francis Crick's legacy for neuroscience: between the alpha and the Omega. PLoS Biol 2: e419.
33. Saunders, NR, Ek, CJ and Dziegielewska, KM (2009). The neonatal blood-brain barrier is functionally effective, and immaturity does not explain differential targeting of AAV9. Nat Biotechnol 27:804-805.
34. Di Pasquale, G and Chiorini, JA (2006). AAV transcytosis through barrier epithelia and endothelium. Mol Ther 13: 506-516. (Pubitemid 43257618)
35. Wolburg, H and Paulus, W (2010). Choroid plexus: biology and pathology. Acta Neuropathol 119: 75-88.
36. Lawlor, PA, Bland, RJ, Mouravlev, A, Young, D and During, MJ (2009). Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther 17: 1692-1702.
37. Xie, J, Xie, Q, Zhang, H, Ameres, SL, Hung, JH and Su, Q (2011). MicroRNA-regulated systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol Ther 19: 526-535.
38. Sun, X, Lu, Y, Bish, LT, Calcedo, R, Wilson, JM and Gao, G (2010). Molecular analysis of vector genome structures after liver transduction by conventional and selfcomplementary adeno-associated viral serotype vectors in murine and nonhuman primate models. Hum Gene Ther 21: 750-761.